Study registry of blood tests for Takayasu arteritis
Part of Heart & circulation, Skin clinical trials.
This study collects information and blood samples (biomarkers) to better understand Takayasu arteritis and how active it is. It may help researchers find tests that support diagnosis and track disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Takayasu arteritis based on specific classification clues or be suspected of it
- You need imaging of your blood vessels (CT angiography or MR angiography) for the study
- You may be eligible if your illness started at age 40 or younger and fits the typical pattern
- You should not have other autoimmune diseases that can look similar (like lupus or ANCA vasculitis)
- You should not have other large-vessel conditions due to infection or age-related giant cell arteritis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects medical information from patients diagnosed with Takayasu arteritis, a rare disease affecting large blood vessels. By joining, you help researchers better understand this condition and improve care for future patients.
This study looks at different types of blood vessel inflammation (vasculitis) to learn more about why they happen and how they progress. By joining, you may help doctors better understand these conditions and improve future treatments.
This trial collects a one-time DNA sample to better understand vasculitis, which are illnesses where blood vessels become inflamed. It may help researchers find why these conditions happen and how they differ across people.
This study looks at people with Takayasu's arteritis that also affects the lungs' blood vessels. Researchers want to understand the disease's behavior and outcomes over time.
This trial is testing two new medications, vunakizumab and ivarmacitinib, to see if they are safe and effective at controlling active Takayasu's arteritis. These medicines work differently from your current treatment, so they might help reduce inflammation and prevent more damage to your blood vessels.
This trial tests an oral medication called deucravacitinib (which is already used for psoriasis) to see if it can calm inflammation in Takayasu's arteritis. If you have active disease despite current treatment, this may offer a new option to help control symptoms and prevent damage.
Hear when a new Takayasu's Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.